Celgene Corporation is expanding its pipeline of innovative cancer drugs, through its acquisition of privately-held biotech, Quanticel Pharmaceuticals. The companies announced today a definitive share purchase agreement under which Celgene will acquire Quanticel in exchange for its proprietary platform for the single-cell genomic analysis of human cancer, as well as …